CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
CAR T-cell Therapy
VISITING CHICAGO? JOIN US IN RECOGNIZING OUR 2018 GIANTS OF CANCER CARE® ON MAY 31st AND VISIT BOOTH 2073 JUNE 2nd-4th!
CAR T-cell Therapy Videos
Dr. Perl on Remaining Challenges with CAR T-Cell Therapy
Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses remaining challenges with chimeric antigen receptor (CAR) T-cell therapy.
Dr. Brentjens Discusses Targets for CAR T-Cell Therapy
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for chimeric antigen receptor (CAR) T-cell therapy.
Dr. Flinn on FDA Approval of Tisagenlecleucel in DLBCL
Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.
Role of CAR T-Cell Therapy in Relapsed/Refractory ALL
Mark R. Litzow, MD; Bijal D. Shah, MD; Aaron C. Logan, MD, PhD; Anthony S. Stein, MD; and Ryan D. Cassaday, MD, discuss the value of CAR T-cell therapy in treating relapsed or refractory acute lymphoblastic leukemia and identify what challenges need to be addressed in this setting.
Practical Perspectives on Acute Lymphocytic Leukemia
Dr. Brentjens on Managing Patients After CAR T-Cell Therapy
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses managing patients after treatment with chimeric antigen receptor (CAR) T-cell therapy.
Dr. Perl on Potential CAR T-Cell Therapies in Hematologic Malignancies
Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses potential chimeric antigen receptor (CAR) T-cells in hematologic malignancies.
Dr. Winter Discusses the ZUMA-7 Trial in DLBCL
Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial (NCT03391466) in diffuse large B-cell lymphoma (DLBCL).
Dr. Coutre Discusses Challenges With CAR T-Cell Therapy in ALL
Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia.
Cost Effectiveness and Future of CAR T Therapy
Krishna V. Komanduri, MD; Michael Pulsipher, MD; David Maloney, MD, PhD; and Stephen J. Schuster, MD, discuss what is known about cost effectiveness of CAR T therapy and provide their closing thoughts on future research.
CAR-T Cell Therapy Use in B-Cell Malignancies
Dr. Bachier Discusses CAR T-Cell Therapy and Stem Cell Transplant
Carlos R. Bachier, MD, program director of Sarah Cannon Center for Blood Cancer, Sarah Cannon Research Institute, discusses the relationship between chimeric antigen receptor (CAR) T-cell therapy and stem cell transplant.
Next Page >>
CAR T-Cell Therapy in DLBCL: Centers of Excellence
Durvalumab Improves Survival in Stage III NSCLC
Study Identifies Factors Linked to Long-Term Survival in Pediatric/Adolescent DIPG
Patel Provides Perspective on Immunotherapy Developments in NSCLC
Selinexor Tested in Combination With Standard Therapy in Multiple Myeloma
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.